home / stock / cue / cue news

CUE News and Press, Cue Biopharma Inc. From 05/05/25

Stock Information
Company Name: Cue Biopharma Inc.
Stock Symbol: CUE
Market: NASDAQ
Website: cuebiopharma.com
Menu
CUE CUE Quote CUE Short CUE News CUE Articles CUE Message Board
Get CUE Alerts

News, Short Squeeze, Breakout and More Instantly...
CUE - Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announ...
CUE - Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

2025-04-15 18:12:03 ET Cue Biopharma, Inc. (CUE) Business Update Call April 15, 2025 04:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Presentation Operator ...

CUE - Cue in pact with Boehringer for autoimmune and inflammatory diseases

2025-04-15 08:00:13 ET More on Cue Biopharma Cue Biopharma stock falls after pricing capital raise of $20M via securities offering Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Bi...

CUE - Cue Biopharma stock falls after pricing capital raise of $20M via securities offering

2025-04-15 01:32:46 ET Cue Biopharma ( NASDAQ: CUE ) announced the pricing details of its underwritten public offering. The offering includes (i) 13,530,780 shares of its common stock, along with warrants to purchase an additional 3,382,695 shares, and (ii) for certain investors...
CUE - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announce...

CUE - Cue biopharma announces public offering

2025-04-14 17:14:24 ET More on Cue Biopharma Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma Read the full article on Seeking Alpha For further details see: Cu...

CUE - Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today ...
CUE - Cue Biopharma GAAP EPS of -$0.13 beats by $0.03, revenue of $1.58M misses by $0.12M

2025-03-31 17:24:12 ET More on Cue Biopharma Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma Read the full article on Seeking Alpha For further details see: Cu...

CUE - Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today re...

CUE - Central Petroleum Limited (CNPTF) West Mereenie 29 Online - Gas Rate Achieves Upside Outcome

Brisbane, Australia (ABN Newswire) - Central Petroleum Limited (ASX:CTP) (FRA:C9J) (OTCMKTS:CNPTF) advises that the new West Mereenie 29 (WM29) well has been tied-in and commenced flowing to sales on 20 January 2025. Following a predetermined ramp up program, a production rate test achieved ~...
Previous 10 Next 10